Journal article

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Adrian G Minson, Katherine Cummins, Lucy Fox, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf Show all

BLOOD ADVANCES | AMER SOC HEMATOLOGY | Published : 2019

Abstract

Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overal..

View full abstract